This retrospective cohort study aimed to assess whether the impact of delayed surgery on survival varies by subtype (hormone [HR]+/HER2−, HR−/HER2−, and HER2+) in patients with loco-regional breast cancer who received surgery as their first treatment between 2010–2017 using the SEER-Medicare. The gene discussed is ERBB2; the disease is breast cancer.